clinical trial · NCT06574347
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Avistone Biotechnology Co., Ltd.·phase2·recruiting·n = 120
Non-Small-Cell Lung CancerVebreltinibOsimertinibPLB1004
brief summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
started
Aug 7, 2024
primary completion
Oct 31, 2026
completion
Jul 31, 2027
last updated
May 21, 2025
detailed description
A Multicenter,Randomized,open-label,Phase II Study to Evaluate the Efficacy and Safety of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients with EGFRm+(exon 19 deletion or exon 21 L858R)/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer.
official title
A Phase II Study of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol